Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|August 8, 2024

Pharma Pulse 8/8/24: Addressing Maternal Health Disparities and Driving Change, Abacavir Increases Cardiovascular Risk in Patients With HIV & more

The latest news for pharma industry insiders.

Addressing Maternal Health Disparities and Driving Change

In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.

Study Finds Abacavir Increases Cardiovascular Risk in Patients With HIV

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

AI is Coming for India’s Famous Tech Hub

Country’s outsourcing companies have added urgency to shift to higher-end services.

Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Two 1-gallon pre-mixed containers of hemodialysis concentrates products CitraPure, RenalPure, or SteriLyte offer easier handling and streamlined workflow for patients, caregivers and healthcare providers.

Matthew Hepburn on LinkedIn

Sharing a work update: I have been asked to be the Vaccine and Therapeutics Lead for the White House Office of Pandemic Preparedness and Response, taking over for Dr. Phil Gomez, these are big shoes to fill! I have been a Senior Advisor on the OPPR team for 4 months, and it has been some of the most rewarding times of my professional career. A great team and a critical mission!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.